Lung meningioma

Summary

Lung meningioma (MONDO:0003638) is a disease. A subtype of lung cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lung meningioma
Mondo ID	MONDO:0003638
DOID	DOID:5764
NCIT	C5668
UMLS	C1334450
MedGen	232712
GARD	0023596
Anatomy (UBERON)	UBERON:0002048
Is cancer (heuristic)	no

Also known as: lung meningioma · lung meningioma (disease) · meningioma (disease) of lung · meningioma of lung · meningioma of the lung · pulmonary meningioma

Disease family

This is a subtype of lung cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › respiratory system cancer › lung cancer › lung meningioma

Related subtypes (6): lung sarcoma, lung lymphoma, lung hilum cancer, lung carcinoma, malignant superior sulcus neoplasm, Graham-Boyle-Troxell syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.